Growth of prostate cancer cells is initially dependent on androgens, and androgen ablation
therapy is used to control tumor growth. Unfortunately, resistance to androgen ablation …

Sulforaphane (SFN), an isothiocyanate first isolated from broccoli, exhibits chemopreventive
properties in prostate cancer cells through mechanisms that are poorly understood. We …

Vorinostat, which is an extensively studied inhibitor against histone deacetylase (HDAC),
shows limited clinical activity to solid tumors. WJ35435, a new hybrid of vorinostat and …

Histone deacetylase inhibitors (HDACi) are promising epigenetic cancer chemotherapeutics
rapidly approaching clinical use. In this study, we tested using in vitro and in vivo models the …

Suberoylanilide hydroxamic acid (SAHA) is the prototype of a family of hybrid polar
compounds that induce growth arrest in transformed cells and show promise for the …

Histone deacetylase inhibitors (HDACi) represent a promising new class of anticancer
agents. In the current investigation, we examined the activity of the HDACi belinostat in …

Tumor suppressor genes are often silenced in human cancer; this can occur by
transcriptional repression by deacetylation in the promoter regions, mediated by histone …

Reversible histone acetylation on lysine residues, regulated by the opposing activities of
histone acetyltransferases and histone deacetylases (HDACs), plays an important role in the …

Background Histone deacetylase (HDAC) inhibitors are emerging as a new class of anti-
cancer drugs that promote cancer cell apoptosis, and include suberoylanilide hydroxamic …

Histone deacetylase (HDAC) inhibitors represent a potential new class of antitumor agents.
Vorinostat (suberoylanilide hydroxamic acid or SAHA) is a potent inhibitor of HDAC activity …